Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Red Light Holland’s subsidiary Filament Health signed an agreement to supply its patented psilocybin candidate PEX010 to GHU Paris Psychiatrie & Neurosciences in France. The supply supports the KETAPSYCHECOG study, a randomized, double-blind, cross-over trial comparing the behavioral and neural effects of psilocybin and ketamine in healthy volunteers.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.